Patients Who Received Lung Transplantation (Previous Year)EOLE VALNCT03453229
Wearable Devices to Assess Physiological Parameters in Lung Transplant Patients
An observational study of Patients Who Received Lung Transplantation (Previous Year), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The present study will be a prospective non-interventional study involving 15 to 20 lung transplant patients. The patient will do as usual Forced Expiratory Volume (FEV1) measures and some physiological parameters will be automatically recorded through the wearable and wireless sensors. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Patients Who Received Lung Transplantation (Previous Year)
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 4 Jul 2019to 4 Jul 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Lung transplant patients
Who may be able to join
- patient over 18 years old
- pulmonary transplant less than a year - consantant - mastering the connected tool
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Measurement of FEV1 and Other Physiological Parameters by Connected Devices in Lung Transplanted Patients
The present study will be a prospective non-interventional study involving 15 to 20 lung transplant patients. The patient will do as usual Forced Expiratory Volume (FEV1) measures and some physiological parameters will be automatically recorded through the wearable and wireless sensors. The spirometer will also be connected but only to transmit stored data, not for real time use. The patient and the physician will not have access to the data until the end of the study. The 6 following physiological parameters will be recorded: heart rate, respiratory rate, body temperature, SPO2, motion, and sleep. The study duration for each patient will be 6 months.
The primary endpoint will be the number of FEV1 measures combined with physiological parameters. This primary endpoint has been chosen because it is easy to obtain. The secondary endpoints will be: - physiological parameters associated with a 10% or higher decrease in FEV1, - correlation between variations of physiological parameters and occurrence of a clinical event (defined by presumption of infection or of graft failure), - interval between the first significant modification of each physiological parameter and the onset of an event, - number of recorded values, - patient's satisfaction. In this pilot phase, there is no real time health advice.
Read the detailed description
Justification of the study: The two main complications responsible for death among lung transplant patients are infection and rejection. In-hospital, 1-year and 5-year mortality is 10%, 20%, and 50%, respectively. The main symptoms are dyspnea, fever, drop in oxygen saturation, drop in pulmonary function tests (FEV1). Investigators hypothesize that surveillance of FEV1 and of several physiologic parameters though connected devices could improve early diagnostic of complications, namely rejection and infection. Surveillance of these patients through connected devices could reduce both mortality and morbidity.
Design of the study: Prospective, observational, monocentric study (Bichat-Hospital, Université Paris 7, France) Main objectives and main endpoint: the main objective is to describe the natural trend of six physiologic parameters (SpO2, heart rate, respiratory rate, cutaneous temperature, physical activity and quality of sleep) and of FEV1 in patients who have benefited from lung transplantation within one year) and to specifically assess the evolution of these parameters a few days before the occurrence of complications. The main criteria of judgment will be mean and standard deviation of these parameters five days before the occurrence of an event, defined by hospitalization for infection and/or graft rejection.
Secondary objectives and secondary endpoints:
The secondary objectives will be:
- To validate metrologic performances of the connected devices.
- To describe the modifications of the physiologic parameters within days before a drop of 10% of FEV1
- To describe the modifications of the physiologic parameters before the occurrence of complications requiring anti-infective and/or anti reject therapies
- To evaluate the interval between modifications of physiologic parameters and the occurrence of infection and/or reject.
- To evaluate the acceptability for the patient and the compliance of connected devices.
The secondary criteria of judgment will be:
- The agreement between physiologic parameters measured through the connected devices and those measured with usual method ("gold standard) during visits in the day-care center
- The mean and standard deviation of the physiologic parameters (including FEV1) recorded for each patient
- The effect of combined physiologic parameters to predict a 10% drop in FEV1, and/or the occurrence of infection and/or the occurrence of graft rejection within 5 days after measurement.
- The interval in days between substantial modifications of physiologic parameters and the occurrence of infection and/or graft rejection.
- The patient's satisfaction measured with a simple questionnaire.
Inclusion criteria
- Adult patients older than 18-years
- Mono or pulmonary transplantation whatever the cause, within the last 12 months
- Inform consent given
- Skill to use connected devices Exclusion criteria
- No exclusion criteria
The devices and the App
Each patient will receive a health kit with the following:
- An App with an electronic formulary allowing the implementation of relevant clinical items: dyspnea, cough, sputum characteristics
- A smartphone
- A connected spirometer
- Wearable devices to record the physiologic parameters.
Duration of the study
Inclusion period: 6 months, Duration of follow-up: 6 months Total duration of the study: 12 months Statistical analysis The distributions of physiologic parameters will be described through mean+/- SD. The comparison of distribution of each physiologic parameter within five days before an event (infection/graft rejection) will allow to define regions in parameter's space associated with an increase in the risk of subsequent events occurrence. For these regions, sensitivity and specificity for predefined thresholds will be calculated. For each event, we will calculate the interval between the entry in a risk region and the occurrence of the event. The standard curve between values recorded through the connected devices and those recorded with the reference measures determined in the hospital will be evaluated with a Bland-Altman representation. The satisfaction questionnaire will be analyzed according to standard methods (distribution of each item, Cronbach alpha coefficient, factorial analyses.
What is being measured
The primary outcome is the main question the study is designed to answer.
time series of SpO2 (in %)
specifically assess the evolution of this parameter a few days before the occurrence of complications (occurrence of infection or graft rejection)
Measured: 6 months
Secondary outcomes (5)
time series of FEV1 (% of theoretical value)
specifically assess the evolution of this parameter a few days before the occurrence of complications (occurrence of infection or graft rejection)
Measured: 6 months
time series of Heart rate (in bpm)
specifically assess the evolution of this parameter a few days before the occurrence of complications (occurrence of infection or graft rejection)
Measured: 6 months
time series of cutaneous temperature (in °C)
specifically assess the evolution of this parameter a few days before the occurrence of complications (occurrence of infection or graft rejection)
Measured: 6 months
time series of respiratory rate (in cycles per minute)
specifically assess the evolution of this parameter a few days before the occurrence of complications (occurrence of infection or graft rejection)
Measured: 6 months
time series of physical activity level (measured in a continuous proprietary scale)
specifically assess the evolution of this parameter a few days before the occurrence of complications (occurrence of infection or graft rejection)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2018
- Study start4 Jul 2019
- Primary completion4 Jan 2020
- Study completion4 Jul 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients Who Received Lung Transplantation (Previous Year)Studies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gilles JEBRAK, Doctor, Principal investigator, Hôpital Bichat 75018 Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03453229
- Sponsor's protocol ID
- 2016GTT1058
- Other IDs
- 2017-A01908-45
- Acronym
- EOLE VAL
- Status last verified
- Mar 2020
- First submitted
- 2 Jan 2018
- Last updated
- 23 Mar 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Measurement of FEV1 and Other Physiological Parameters by Connected Devices in Lung Transplanted Patients
- ClinicalTrials.gov ID
- NCT03453229
- Acronym / sponsor ID
- EOLE VAL / 2016GTT1058
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 4 Jul 2019 (actual)
- Primary completion
- 4 Jan 2020 (actual)
- Study completion
- 4 Jul 2020 (estimated)
- First posted
- 5 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study will be a prospective non-interventional study involving 15 to 20 lung transplant patients. The patient will do as usual Forced Expiratory Volume (FEV1) measures and some physiological parameters will be automatically recorded through the wearable and wireless sensors. The spirometer will also be connected but only to transmit stored data, not for real time use. The patient and the physician will not have access to the data until the end of the study. The 6 following physiological parameters will be recorded: heart rate, respiratory rate, body temperature, SPO2, motion, and sleep. The study duration for each patient will be 6 months.
The primary endpoint will be the number of FEV1 measures combined with physiological parameters. This primary endpoint has been chosen because it is easy to obtain. The secondary endpoints will be: - physiological parameters associated with a 10% or higher decrease in FEV1, - correlation between variations of physiological parameters and occurrence of a clinical event (defined by presumption of infection or of graft failure), - interval between the first significant modification of each physiological parameter and the onset of an event, - number of recorded values, - patient's satisfaction. In this pilot phase, there is no real time health advice.
Detailed description
Justification of the study: The two main complications responsible for death among lung transplant patients are infection and rejection. In-hospital, 1-year and 5-year mortality is 10%, 20%, and 50%, respectively. The main symptoms are dyspnea, fever, drop in oxygen saturation, drop in pulmonary function tests (FEV1). Investigators hypothesize that surveillance of FEV1 and of several physiologic parameters though connected devices could improve early diagnostic of complications, namely rejection and infection. Surveillance of these patients through connected devices could reduce both mortality and morbidity.
Design of the study: Prospective, observational, monocentric study (Bichat-Hospital, Université Paris 7, France) Main objectives and main endpoint: the main objective is to describe the natural trend of six physiologic parameters (SpO2, heart rate, respiratory rate, cutaneous temperature, physical activity and quality of sleep) and of FEV1 in patients who have benefited from lung transplantation within one year) and to specifically assess the evolution of these parameters a few days before the occurrence of complications. The main criteria of judgment will be mean and standard deviation of these parameters five days before the occurrence of an event, defined by hospitalization for infection and/or graft rejection.
Secondary objectives and secondary endpoints:
The secondary objectives will be:
- To validate metrologic performances of the connected devices.
- To describe the modifications of the physiologic parameters within days before a drop of 10% of FEV1
- To describe the modifications of the physiologic parameters before the occurrence of complications requiring anti-infective and/or anti reject therapies
- To evaluate the interval between modifications of physiologic parameters and the occurrence of infection and/or reject.
- To evaluate the acceptability for the patient and the compliance of connected devices.
The secondary criteria of judgment will be:
- The agreement between physiologic parameters measured through the connected devices and those measured with usual method ("gold standard) during visits in the day-care center
- The mean and standard deviation of the physiologic parameters (including FEV1) recorded for each patient
- The effect of combined physiologic parameters to predict a 10% drop in FEV1, and/or the occurrence of infection and/or the occurrence of graft rejection within 5 days after measurement.
- The interval in days between substantial modifications of physiologic parameters and the occurrence of infection and/or graft rejection.
- The patient's satisfaction measured with a simple questionnaire.
Inclusion criteria
- Adult patients older than 18-years
- Mono or pulmonary transplantation whatever the cause, within the last 12 months
- Inform consent given
- Skill to use connected devices Exclusion criteria
- No exclusion criteria
The devices and the App
Each patient will receive a health kit with the following:
- An App with an electronic formulary allowing the implementation of relevant clinical items: dyspnea, cough, sputum characteristics
- A smartphone
- A connected spirometer
- Wearable devices to record the physiologic parameters.
Duration of the study
Inclusion period: 6 months, Duration of follow-up: 6 months Total duration of the study: 12 months Statistical analysis The distributions of physiologic parameters will be described through mean+/- SD. The comparison of distribution of each physiologic parameter within five days before an event (infection/graft rejection) will allow to define regions in parameter's space associated with an increase in the risk of subsequent events occurrence. For these regions, sensitivity and specificity for predefined thresholds will be calculated. For each event, we will calculate the interval between the entry in a risk region and the occurrence of the event. The standard curve between values recorded through the connected devices and those recorded with the reference measures determined in the hospital will be evaluated with a Bland-Altman representation. The satisfaction questionnaire will be analyzed according to standard methods (distribution of each item, Cronbach alpha coefficient, factorial analyses.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Lung transplant patients
Key inclusion criteria (2 listed)
- patient over 18 years old
- pulmonary transplant less than a year - consantant - mastering the connected tool
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
time series of SpO2 (in %)
Time frame: 6 months
specifically assess the evolution of this parameter a few days before the occurrence of complications (occurrence of infection or graft rejection)
5 secondary outcomes
time series of FEV1 (% of theoretical value)
Time frame: 6 months
time series of Heart rate (in bpm)
Time frame: 6 months
time series of cutaneous temperature (in °C)
Time frame: 6 months
time series of respiratory rate (in cycles per minute)
Time frame: 6 months
time series of physical activity level (measured in a continuous proprietary scale)
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2020.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gilles JEBRAK, Doctor principal investigator
Hôpital Bichat 75018 Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patients Who Received Lung Transplantation (Previous Year), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Gilles JEBRAK, Doctor (01.40.25.69.16, gilles.jebrak@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
time series of SpO2 (in %) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2020.